Gilead Raises Full-Year Product Sales Guidance to $31B
Gilead raised its full-year product sales guidance to $31 billion, from a prior range of $30.1 billion to $30.4 billion.
Story updates
08:05:12 PM UTC
SquawkNews
Gilead reported Q3 2026 product sales ex-Veklury up 16% to $8.2B, led by HIV (+18%) and Trodelvy. The company raised full-year 2026 base business revenue guidance and noted GAAP/non-GAAP diluted loss per share include ~$9.88 impact from $12.4B acquired IPR&D.Material DetailsContext by AI AnalystThi…